Boris Johnson says he is not worried about the reports as the UK regulator had judged it as “effective across all age groups”.
It comes after Reuters reported Germany’s vaccine committee made the recommendation, citing insufficient data about how effective the jab is for older people, not because of any safety concerns.
But UK prime minister Boris Johnson said he was not worried because Britain’s medicines regulator had judged it is “effective across all age groups and provides a good immune response across all age groups”.
He added “I don’t agree” with the apparent assessment in Germany.
A spokesperson for AstraZeneca said its research findings “support efficacy in the over 65 years age group”.
Dr Mary Ramsay, head of immunisations at PHE, said: “There were too few cases in older people in the AstraZeneca trials to observe precise levels of protection in this group, but data on immune responses were very reassuring.
“The risk of severe disease and death increase exponentially with age – the priority is to vaccinate as many vulnerable people as possible with either vaccine, to protect more people and save more lives.”
The European Medicines Agency is expected to make a decision on whether to approve AstraZeneca’s COVID-19 vaccine on Friday.
It comes as Brussels and the pharmaceutical giant are embroiled in an open, escalating row over the EU’s slow start to its inoculation programme.
Belgian authorities said on Thursday they had carried out an inspection of a vaccine factory in the town of Seneffe on instruction from the EU Commission.
AstraZeneca announced it would have to cut the amount of jabs delivered to the bloc’s 27 nations before the end of March from 80 million to 31 million, citing production issues at European factories.
But the EU’s health commissioner Stella Kyriakides said AstraZeneca should make up for the shortfall by shipping over jabs made at its plants in Britain instead.
Sky News understands that AstraZeneca has agreed to publish its supply contract with the EU.
Professor Stephen Evans from the London School of Hygiene and Tropical Medicine said there is “no reason at all for anyone in the UK or elsewhere to think that this Oxford/AstraZeneca vaccine is ineffective at any age”.
He added: “Its ability to be delivered to people in GP surgeries and care homes makes it a vital component in the attempts to reduce hospitalisation and deaths, especially in the elderly.”
Prof Andrew Pollard, chair of the UK government’s Joint Committee on Vaccination and Immunisation, also said: “There is limited information available on efficacy in participants aged 65 or over, although there is nothing to suggest lack of protection.”